“We have the capacity to produce over 10M COVID-19 tests per week globally”
Bio Spectrum|October 2020
Thermo Fisher Scientific, the world leader in serving science, is continuously working to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments.
Dr Manbeena Chawla
“We have the capacity to produce over 10M COVID-19 tests per week globally”

The company is now supporting over 200 projects globally. The company is also supporting multiple vaccine programmes globally that are in or entering human clinical trials, providing critical capacity and expertise that has accelerated development and readiness by months. In addition to its work on COVID-19-related vaccines and therapies, the company continues to ensure that patients undergoing clinical trials continue to receive the critical medicines they need during this crisis. Amit Chopra, Managing Director, India and Middle East, Thermo Fisher Scientific, Mumbai recently spoke to BioSpectrum about the company’s initiatives to counter COVID-19, particularly in India. Edited excerpts;

How is Thermo Fisher Scientific expanding its diagnostic capacity to fight the global pandemic?

At Thermo Fisher Scientific, our mission is to enable our customers to make the world healthier, cleaner, and safer. Globally, we saw a significant increase in the spread of the virus and our customers were getting inundated. As reliable partners, our primary objective was to scale our offerings to enable them to better navigate through this pandemic. We have been actively involved in understanding the structure of the virus, developing new diagnostic tests, providing personal protective equipment, reagents, and other laboratory essential instruments, to providing tools for vaccine research and development, clinical trials and even manufacturing some of the therapeutics. TaqPath COVID-19 Combo Kits were one of the first tests to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and are being extensively used across the world.

هذه القصة مأخوذة من طبعة October 2020 من Bio Spectrum.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

هذه القصة مأخوذة من طبعة October 2020 من Bio Spectrum.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

المزيد من القصص من BIO SPECTRUM مشاهدة الكل
Economic Survey Lays Focus On Mental Healthcare For The First Time
Bio Spectrum

Economic Survey Lays Focus On Mental Healthcare For The First Time

For the first time ever, the Economic Survey 2023-24 tabled by the Union Minister of Finance and Corporate Affairs Nirmala Sitharaman in Parliament recently, talks extensively about mental health, its significance and implications on policy recommendations.

time-read
1 min  |
September 2024
IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus
Bio Spectrum

IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus

Indian Institute of Technology Guwahati (IIT-G) researchers have investigated the biochemistry of the African Swine Fever Virus (ASFV) protein, focusing on understanding the biochemical processes of infection to devise effective control strategies.

time-read
1 min  |
September 2024
13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors
Bio Spectrum

13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors

The 13th edition of Bengaluru INDIA NANO 2024, organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science & Technology Promotion Society (KSTePS), and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) concluded on August 3 with participation of 1018 delegates, 11 countries including Korea, Morocco, USA, UK, France, Canada, Germany, Netherlands, Russia, Japan, and Poland, 49 exhibitors comprising 21 startups and 28 industry and institutes, and 200 posters. The exhibition had a footfall of 3,000+ visitors.

time-read
3 mins  |
September 2024
Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle
Bio Spectrum

Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle

The news has been around for a while which has put a big question mark ahead of the Indian nutraceuticals industry.

time-read
9 mins  |
September 2024
Can India Reclaim API Throne from China?
Bio Spectrum

Can India Reclaim API Throne from China?

Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs).

time-read
10+ mins  |
September 2024
JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana
Bio Spectrum

JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana

JRS Pharma, a leading manufacturer of excipients, in partnership with Gujarat Microwax, has commissioned a new manufacturing facility for cotton-based croscarmellose sodium.

time-read
1 min  |
September 2024
NovaLead's patented repurposed drug for treating DFU gets CDSCO approval
Bio Spectrum

NovaLead's patented repurposed drug for treating DFU gets CDSCO approval

Pune-based NovaLead Pharma has announced that the drug regulator in India, Central Drugs Standard Control Organisation (CDSCO), has approved their patented Repurposed Drug for treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need.

time-read
1 min  |
September 2024
Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda
Bio Spectrum

Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda

Delhi-based pharma company Medicamen Organics has taken a significant step in its global expansion strategy by signing a Memorandum of Understanding (MoU) with Depot Pharmacy Yego in Rwanda.

time-read
1 min  |
September 2024
Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr
Bio Spectrum

Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr

Mankind Pharma has entered into a definitive agreement to acquire a 100 per cent stake in Bharat Serums and Vaccines Limited (BSV) from Advent International, for an enterprise value of approx.

time-read
1 min  |
September 2024
Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence
Bio Spectrum

Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence

Mumbai-based Thyrocare, a leading diagnostic and preventive healthcare service provider in India, has entered into a Business Transfer Agreement with Polo Labs to acquire their pathology diagnostic business.

time-read
1 min  |
September 2024